Search results

631 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Cancer service guidelines Remove Cancer service guidelines filter

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

In development [GID-TA10631] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

In development [GID-TA10620] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Third molars (impacted) - prophylactic removal [ID898]

In development [GID-TAG525] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

In development [GID-TA10427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]

In development [GID-TA10643] Expected publication date: 16 June 2021

Type

Technology appraisal guidance

Status

In development
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

Proposed [GID-TA10748] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Proposed [GID-TA10749] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

Proposed [GID-TA10750] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]

Proposed [GID-TA10751] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

Proposed [GID-TA10752] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Melphalan flufenamide for Multiple myeloma in Relapsing or refractory In combination with dexamethasone [ID3862]

Proposed [GID-TA10744] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

Proposed [GID-TA10745] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]

Proposed [GID-TA10746] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

Proposed [GID-TA10747] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omburtamab for treating relapsed neuroblastoma [ID1664]

In development [GID-TA10608] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

Proposed [GID-TA10652] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

In development [GID-TA10272] Expected publication date: 14 July 2021

Type

Technology appraisal guidance

Status

In development
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Proposed [GID-TA10715] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

Proposed [GID-TA10717] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

Proposed [GID-TA10718] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]

Proposed [GID-TA10719] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibalizumab in combination with other antiretrovirals for multidrug-resistant HIV-1 [ID2720]

Proposed [GID-TA10657] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abicipar pegol for treating wet age-related macular degeneration ID1533

In development [GID-TA10511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

In development [GID-TA10442] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

In development [GID-TA10397] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for untreated pancreatic cancer [ID1074]

In development [GID-TA10689] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

Proposed [GID-TA10662] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

In development [GID-TA10686] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

In development [GID-TA10687] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
MT582 AnaConDa

In development [GID-MT556] Expected publication date: 23 February 2022

Type

Medical technologies guidance

Status

In development